What they were paid
SUPERNUS PHARMACEUTICALS Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $76,000 | $150,002 | $150,011 | $0 | $376,013 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SUPERNUS PHARMACEUTICALS, INC. DEF 14A filed April 30, 2026, accession 0001104659-26-053111, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025SUPERNUS PHARMACEUTICALS pays directors a $50,000 cash retainer and $300,000 in RSUs and Options (50/50 split).
Committees
FY2025 · as the proxy prints themNominating/Governance · Science (Chair)
The rest of the SUPERNUS PHARMACEUTICALS board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Bethany L. Sensenig | Independent Director | $362,513 |
| Charles W. Newhall, III | Chair of the Board | $417,013 |
| Frederick M. Hudson | Independent Director | $385,013 |
| Georges Gemayel | Independent Director | $398,513 |
| Jack A. Khattar | Director | $0 |
The full SUPERNUS PHARMACEUTICALS compensation record
free company briefThis page is one director within SUPERNUS PHARMACEUTICALS's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat